US Executive Officer Management Changes SEC — June 04, 2026

04-06-2026

AVITA Medical, Inc. held its 2026 Annual Meeting on June 3, 2026, where stockholders approved all 15 proposals, including the election of all seven director nominees, an increase in the non-executive director cash fee pool from $750,000 to $900,000 per annum, and the issuance of equity awards to directors and officers. However, several proposals received notable opposition, with votes against ranging from approximately 1.8 million to 2.7 million shares, and broker non-votes of 3.89 million shares on most items, indicating mixed shareholder sentiment on certain governance and compensation matters.

• · All seven director nominees were elected with votes for ranging from 10,700,424 to 11,176,792, and votes withheld from 525,113 to 1,001,481.
• · Ratification of Grant Thornton LLP as independent auditor passed with 14,962,654 votes for, 255,151 against, and 374,642 abstentions.
• · Proposal to increase director fee pool to $900,000 passed with 8,582,602 for, 2,710,656 against, and 408,647 abstentions (plus 3,890,542 broker non-votes).
• · Annual equity grants to each non-executive director (22,214 RSUs and 16,133 options) passed with votes for ranging from 8,722,810 to 8,869,562, and votes against from 2,411,009 to 2,544,450.
• · Initial grant to Dr. Michael Tarnoff (26,250 RSUs and 19,063 options) passed with 8,791,498 for, 2,433,367 against, and 477,040 abstentions.
• · Initial grant to Joseph Woody (40,547 RSUs and 29,446 options) passed with 8,863,312 for, 2,395,376 against, and 443,217 abstentions.
• · Advisory vote on executive compensation (Say-on-Pay) passed with 8,918,272 for, 2,202,213 against, and 581,420 abstentions.
• · Advisory vote on frequency of Say-on-Pay favored 1 year with 9,545,151 votes, versus 924,743 for 2 years, 650,252 for 3 years, and 581,759 abstentions.
• · Issuance of warrants to Perceptive (up to 650,000 shares, 10-year term) passed with 9,322,532 for, 1,769,627 against, and 609,746 abstentions.
• · Approval to issue additional 10% equity securities under ASX Rule 7.1A passed with 8,947,195 for, 2,223,106 against, and 531,604 abstentions.

04-06-2026

Avery Dennison announced the appointment of Danny Allouche as President of its Materials Group. Allouche, previously SVP and Chief Strategy and Corporate Development Officer (and interim CFO in late 2024), brings 16 years of internal experience across strategy, M&A, and treasury. The appointment reflects an internal succession but does not disclose separate financial metrics for the Materials Group vs the broader company.

• · Danny Allouche served as interim CFO for a brief period beginning in late 2024.
• · Allouche holds an MBA from UCLA Anderson School of Management and a bachelor’s in economics from Northwestern University.
• · Avery Dennison employs approximately 35,000 employees in more than 50 countries.
• · Reported sales in 2025 were $8.9B.

04-06-2026

BeyondSpring Inc. announced a leadership transition effective July 1, 2026, designed to sharpen execution on its confirmatory Phase 3 DUBLIN-4 trial for Plinabulin in NSCLC. Founder Dr. Lan Huang will remain Chairman but cede the CEO role to Min Qiu, while Dr. Jen Majeti becomes Vice Chairman and Na Li becomes CFO. The restructuring aims to give each of BeyondSpring and SEED Therapeutics (where Dr. Huang is CEO) a fully dedicated executive leader. However, the departure of the founder from day-to-day operations introduces key-person transition risk, and no financial guidance or enrollment timelines were disclosed, creating uncertainty on execution pace and capital needs.

• · IP portfolio for Plinabulin includes composition-of-matter protection extending through 2036 with potential Hatch-Waxman extension to 2041.
• · Incoming CEO Min Qiu previously led an RMB 1.3 billion licensing collaboration at Hengrui Pharma and is fluent in Chinese, English, and Japanese.
• · New CFO Na Li holds Shanghai Stock Exchange Board Secretary qualification and has board secretary experience for Main Board and Third Board-listed companies.
• · BeyondSpring retains a meaningful equity stake in SEED Therapeutics.
• · SEED Therapeutics has advanced its lead RBM39 degrader (ST-01156) into Phase 1 development with cornerstone investors Eli Lilly and Eisai.
• · DUBLIN-3 results published in The Lancet Respiratory Medicine (2024).

04-06-2026

CRISPR Therapeutics AG filed an 8-K on June 4, 2026, disclosing amendments to its Articles of Association, including the adoption of a capital band authorizing the Board of Directors to increase share capital up to CHF 3,521,838.51 (from CHF 2,957,983.32) through the issuance of up to 117,394,617 registered shares (nominal value CHF 0.03 each) until June 8, 2028, and the creation of conditional capital for bonds and similar instruments of up to CHF 281,008.41 (9,366,947 shares). The amendments also expand the Board's flexibility in excluding shareholder subscription rights for specific purposes.

• · Capital band expires on June 8, 2028 (or earlier if limit is reached), and allows multiple increases up to the upper limit of CHF 3,521,838.51.
• · Board may exclude shareholder subscription rights for several purposes: market-price-based issuance, acquisitions, strategic partnerships, over-allotment ('greenshoe') up to 20% of shares, fast flexible capital raising (private placements), and defense against unsolicited takeover bids (shareholder exceeding 15% without a Board-recommended offer).
• · Conditional capital for bonds/debt instruments has a 10-year exercise period for option rights and 20 years for conversion rights from the issuance date.
• · The amendments were filed as Exhibit 3.1 to the 8-K.

04-06-2026

Kura Oncology, Inc. filed an 8-K on June 4, 2026, reporting that stockholders approved an amendment to the Amended and Restated 2014 Equity Incentive Plan, increasing the share reserve by 6,500,000 shares to a total of 41,077,686 shares. The filing also covers standard administrative provisions for equity awards, including options, restricted stock, and performance awards, with no specific financial results or officer changes detailed.

• · The plan was originally adopted in 2015 and has been amended multiple times, with the latest stockholder approval on June 4, 2026.
• · The share reserve includes shares from prior annual increases and stockholder approvals from 2023 (4,050,000), 2024 (5,500,000), and 2025 (4,750,000).
• · Full Value Awards reduce the share reserve by 1.44 shares per share issued, while options/SARs with exercise price at least 100% of fair market value reduce it by 1 share per share.
• · The plan allows for delegation of administration to a committee and permits grants to employees, directors, and consultants.

04-06-2026

Ideal Power Inc. held its 2026 Annual Meeting on June 3, 2026, where stockholders approved all four proposals, including the election of five directors, ratification of BPM LLP as auditor, advisory approval of executive compensation, and the amended 2013 Equity Incentive Plan. The plan was amended to increase authorized shares by 800,000 and extend the term to June 3, 2036. The meeting had a quorum of 57.68% of outstanding shares (7,010,910 shares represented).

• · All five director nominees were elected with 'For' votes ranging from 4,139,174 to 4,273,623; broker non-votes were 2,720,323 for each.
• · Ratification of BPM LLP as auditor passed overwhelmingly with 6,988,321 'For' votes, 14,395 'Against', and 8,194 'Abstain'.
• · Advisory vote on executive compensation (Say-on-Pay) received 3,588,466 'For', 625,041 'Against', and 77,080 'Abstain'.
• · Approval of the amended 2013 Equity Incentive Plan received 3,624,425 'For', 601,975 'Against', and 64,187 'Abstain'.
• · The 2013 Plan term was extended to June 3, 2036.
• · The plan amendment also modified terms relating to repricing, repurchase, or cancellation of options without stockholder approval.

04-06-2026

Gencor Industries appointed Raymond Cole as Interim Chief Financial Officer, effective June 1, 2026. Mr. Cole brings recent CFO experience at ECD Auto Design (de-SPAC, capital raises, acquisitions) and consulting in specialty sales. He will serve on an at-will basis with a monthly consulting fee of $32,500.

04-06-2026

On May 29, 2026, David L. Duvall resigned from the board of directors of Core Molding Technologies, Inc., effective June 1, 2026, due to his previously announced retirement as President & CEO. The resignation was not due to any disagreement with the company, management, or the board.

• · David L. Duvall's resignation as director was effective June 1, 2026.
• · The resignation was related to his previously announced retirement as President & CEO.
• · No disagreement with the company, management, or the board was cited.

04-06-2026

CV Sciences held its 2026 Annual Meeting on June 2, 2026, with 60.1% quorum. Stockholders elected three directors (Dr. Jamie Corroon, Joseph Dowling, Bill McCorkle) and ratified Haskell & White LLP as auditor. However, a proposal to authorize a reverse stock split (ratio 1:10 to 1:800) was not approved, with 59,628,926 votes against versus 48,496,747 for.

• · Record date for the meeting was April 6, 2026.
• · Reverse stock split proposal failed: 48,496,747 for, 59,628,926 against, 8,109,111 abstain.
• · Auditor ratification passed with 102,384,289 for, 12,488,529 against, 1,361,966 abstain.
• · Director votes: Corroon 39,505,495 for; Dowling 37,674,977 for; McCorkle 22,671,092 for (with 17,168,371 abstain).

04-06-2026

OnKure Therapeutics held its 2026 Annual Meeting on June 3, 2026, where stockholders elected three Class II directors (R. Michael Carruthers, Valerie M. Jansen, Edward T. Mathers), ratified KPMG LLP as independent auditor, and approved an amended and restated 2024 Equity Incentive Plan. The plan amendments include a one-time increase of 3,231,638 shares (approximately 8% of outstanding shares) and removal of the annual share limit while maintaining a 5% evergreen provision. The company also filed an 8-K reporting these items.

• · The company is an emerging growth company and has not elected to use the extended transition period for complying with new financial accounting standards.
• · The reverse stock split of 1:10 was effected on October 4, 2024.
• · The A&R 2024 Plan limits the number of shares that can be issued as incentive stock options.
• · Broker non-votes were 5,466,123 for all director proposals and the equity plan proposal.

04-06-2026

iHeartMedia held its 2026 Annual Meeting on June 4, 2026, where stockholders approved the second amendment to the 2021 Long-Term Incentive Award Plan, increasing authorized shares by 13,000,000 to a total of 32,000,000 and extending the grant period through June 4, 2036. All eight director nominees were elected, Ernst & Young LLP was ratified as auditor, and the advisory say-on-pay proposal passed with 83,318,864 votes for and 15,393,581 against, indicating notable dissent of approximately 15.6% of votes cast.

• · The Amendment extends the right to grant awards under the Amended Plan through June 4, 2036, with incentive stock options limited to April 7, 2036.
• · Proposal 3 (advisory say-on-pay) received 83,318,864 votes FOR, 15,393,581 AGAINST, and 750,265 ABSTAINED, with 8,957,386 broker non-votes.
• · Proposal 4 (approval of the Plan amendment) received 94,485,819 votes FOR, 4,225,053 AGAINST, and 751,838 ABSTAINED, with 8,957,386 broker non-votes.
• · All director nominees received over 90 million votes FOR each, with James A. Rasulo receiving the lowest support at 90,172,403 FOR and 9,290,307 WITHHELD.

04-06-2026

Interface Inc. amended its Executive Bonus Plan on June 2, 2026, increasing the maximum annual bonus from $1.85 million to $3.0 million per participant. The amendment also introduces a forfeiture provision for participants terminated for cause on or before March 15 of the year following the performance period, even if they completed the full period. No financial results or period-over-period comparisons were provided in this filing.

• · The amendment was approved by the Compensation & Talent Development Committee of the Board of Directors.
• · The forfeiture provision applies to participants terminated for cause on or before March 15 of the year following the performance period.
• · The full text of the Amended Plan is attached as Exhibit 10.1 to the 8-K filing.

04-06-2026

Baldwin Insurance Group appointed Johnathan Daniel as interim Chief Accounting Officer effective mid-to-late June 2026 during Corbyn Lichon's maternity leave. At the 2026 Annual Meeting, shareholders elected four Class I directors, approved say-on-pay compensation, and ratified PwC as auditor. No negative or flat metrics were reported.

• · Johnathan Daniel, age 41, has been Executive Director of Finance since January 1, 2026.
• · Daniel previously served as CFO of CAC Group (acquired by Baldwin in Jan 2026) from July 2025 to Dec 2025.
• · Daniel is a CPA and Accredited in Business Valuation.
• · Employment Agreement provides for indefinite term, 120-day notice by Daniel, and standard benefits including open PTO.
• · Annual Meeting voting results: Lowry Baldwin received 94,869,684 For, 4,282,765 Withheld; Sathish Muthukrishnan 98,197,244 For, 955,205 Withheld; Sunita Parasuraman 98,076,188 For, 1,076,261 Withheld; Ellyn Shook 81,501,294 For, 17,651,155 Withheld.
• · Say-on-Pay: 94,240,293 For, 4,125,200 Against, 786,956 Abstain.
• · Ratification of PwC: 109,549,914 For, 62,128 Against, 50,867 Abstain.

04-06-2026

Seneca Bancorp, Inc. announced the retirement of EVP and CFO Vincent Fazio effective June 30, 2026, and the appointment of Angela Krezmer as his successor effective July 1, 2026. The company also appointed Angelo Testani as EVP and Chief Banking Officer, and entered into an amended employment agreement with CEO Joseph Vitale. The changes reflect a leadership transition with new executives receiving base salaries of $220,000 (Krezmer) and $201,375 (Testani), while Fazio will receive a modest $1,000 monthly consulting fee and an increased SERP benefit of $15,000 annually.

• · Angela Krezmer previously served as President, CEO, and CFO of Generations Bank and Generations Bancorp NY, Inc. through their acquisition by ESL Federal Credit Union.
• · Angelo Testani has served as Senior Vice President of Commercial Lending since 2016.
• · The employment agreements for Krezmer and Testani have an initial term through December 31, 2028, with automatic one-year renewals.
• · Severance for change-in-control termination includes three times the sum of base salary and highest annual cash bonus, plus COBRA premium reimbursement for 36 months.
• · Non-competition and non-solicitation restrictions apply for one year after termination (other than following a change in control).
• · CEO Joseph Vitale's amended employment agreement runs through December 31, 2028, with automatic renewals.

04-06-2026

Sarepta Therapeutics held its 2026 Annual Meeting on June 4, 2026, where stockholders approved the 2026 Equity Incentive Plan (6,286,841 shares authorized) and the 2026 Employee Stock Purchase Plan (1,500,000 shares authorized), replacing prior plans. All five director nominees were elected, though Deirdre Connelly received significant opposition with 14,213,242 votes against (21.0% of votes cast). The advisory vote on executive compensation passed with 45,185,398 for and 22,373,065 against (33.1% opposed), indicating notable shareholder dissent.

• · KPMG LLP was ratified as independent auditor for 2026 with 79,907,368 for, 2,110,136 against, and 291,784 abstentions.
• · Director Hans Wigzell received 10,663,180 votes against (15.7% of votes cast), the second-highest opposition after Connelly.
• · The 2026 Equity Incentive Plan was approved with 63,233,193 for and 4,395,283 against (6.5% opposed).
• · The 2026 ESPP was approved with 67,098,699 for and only 532,525 against (0.8% opposed).
• · Broker non-votes totaled 14,616,281 on all proposals except auditor ratification.

04-06-2026

Abacus Global Management, Inc. held its Annual Meeting on June 3, 2026, where shareholders approved the 2026 Long-Term Equity Incentive Plan, ratified KPMG LLP as independent auditor, and re-elected directors Jay Jackson and Thomas W. Corbett, Jr. as Class III directors. The advisory vote on executive compensation passed, and shareholders selected a one-year frequency for future Say-on-Pay votes. However, the 2026 LTIP and the advisory compensation vote each received over 8 million votes against, indicating notable shareholder dissent.

• · The 2026 LTIP became effective immediately upon shareholder approval on June 3, 2026.
• · The 2026 LTIP is described in Proposal 3 of the Definitive Proxy Statement filed on April 21, 2026.
• · The full text of the 2026 LTIP is filed as Exhibit 10.1 to this Form 8-K.
• · Jay Jackson received 72,107,921 votes FOR and 849,086 WITHHELD; Thomas W. Corbett, Jr. received 67,618,868 FOR and 5,338,139 WITHHELD.
• · Ratification of KPMG LLP passed with 78,073,928 FOR, 33,924 AGAINST, and 65,711 abstentions.
• · Advisory vote on executive compensation passed with 62,263,261 FOR, 8,351,613 AGAINST, and 2,342,133 abstentions.
• · The frequency vote resulted in 52,503,249 FOR 1 year, 54,412 FOR 2 years, and 18,117,425 FOR 3 years, with 2,281,921 abstentions.

04-06-2026

Globus Medical, Inc. held its 2026 Annual Meeting on June 3, 2026, where stockholders approved an amendment to the 2021 Equity Incentive Plan, increasing authorized shares by 1,000,000 to a total of 12,000,000 shares. All four proposals were approved, including the election of two Class II directors, ratification of Deloitte & Touche as auditor, and advisory approval of 2025 executive compensation. The amendment to the equity plan received significant support but also notable opposition, with 75,266,538 votes against.

• · The 2021 Equity Incentive Plan Amendment increased the aggregate number of shares authorized for issuance to 12,000,000 shares of Class A Common Stock.
• · The amendment also increased the aggregate number of shares that may be issued under incentive stock options from 11,000,000 to 12,000,000.
• · Proposal 2 (Equity Plan Amendment) received 246,228,534 votes in favor, 75,266,538 against, and 79,135 abstentions, with 6,902,949 broker non-votes.
• · Proposal 3 (Auditor ratification) passed with 327,965,803 votes in favor, 467,955 against, and 43,398 abstentions.
• · Proposal 4 (Advisory say-on-pay) passed with 316,289,675 votes in favor, 5,212,943 against, and 71,589 abstentions.
• · No other items were submitted for stockholder action at the Annual Meeting.

04-06-2026

Bally's Chicago, Inc. disclosed the appointment of Cheryl Ash as Senior Vice President, Finance and North America and CFO of Bally's Chicago, effective May 29, 2026. Her annual compensation includes a base salary of $350,000, a target bonus of 75% of base salary, and eligibility for future equity grants. No negative or flat performance metrics are present in this filing.

• · Cheryl Ash's employment agreement is with Bally's Management Group, LLC, a subsidiary of Bally's Corporation.
• · The base salary of $350,000 will be reviewed annually.
• · Future equity grants are subject to determination by the compensation committee of Bally's Corporation board of directors.
• · The filing includes a cautionary note regarding forward-looking statements.

04-06-2026

BioMarin Pharmaceutical Inc. held its 2026 Annual Meeting of Stockholders on June 2, 2026, where all ten director nominees were elected and all four proposals were approved, including the ratification of KPMG LLP as independent auditor, an advisory vote on executive compensation, and an amendment to the 2017 Equity Incentive Plan to increase authorized shares by 7,650,000. Notably, director Ian T. Clark received the lowest support with 144,380,101 votes for and 19,160,530 against (11.7% against), while the advisory say-on-pay proposal had 21,287,767 votes against (13.0% of votes cast), indicating notable shareholder dissent on compensation.

• · Director Ian T. Clark received 144,380,101 votes for and 19,160,530 against, the highest number of against votes among all nominees.
• · The advisory say-on-pay proposal had 142,742,800 votes for, 21,287,767 against, and 163,683 abstentions, with 11,619,042 broker non-votes.
• · The Plan Amendment was approved with 158,561,867 votes for, 5,480,380 against, and 152,003 abstentions.
• · KPMG LLP was ratified as independent auditor for fiscal year ending December 31, 2026, with 170,867,335 votes for, 4,850,526 against, and 95,431 abstentions.
• · All director nominees were elected, with the lowest support for Ian T. Clark (144,380,101 for) and the highest for Alexander Hardy (163,115,633 for).

04-06-2026

W&T Offshore, Inc. held its 2026 annual meeting on June 3, 2026, where shareholders approved an amendment to the 2023 Incentive Compensation Plan increasing the number of shares available for issuance from 10,000,000 to 22,000,000. All six director nominees were elected, and the advisory vote on executive compensation was approved. The ratification of Deloitte & Touche LLP as independent auditor was also approved with strong support.

• · The advisory vote on executive compensation (Proposal 2) had 10,207,396 votes against, representing about 11% of votes cast (excluding broker non-votes).
• · The Plan amendment (Proposal 4) had 17,404,719 votes against (approximately 18% of votes cast excluding broker non-votes), showing notable shareholder dissent.
• · All six director nominees received over 89 million votes 'For', with the lowest support for Daniel O. Conwill IV at 89,060,071 (with 3,775,296 withheld).
• · Broker non-votes totaled 26,334,136 on all director elections and on Proposals 2 and 4, indicating significant institutional ownership not voting on non-routine matters.
• · Ratification of Deloitte & Touche (Proposal 3) was overwhelmingly approved with 118,090,955 votes For, only 516,304 Against, and no broker non-votes (a routine matter).

04-06-2026

Direct Digital Holdings, Inc. (DRCT) announced the appointment of Ohad Harlev to its Board of Directors, effective June 4, 2026. Mr. Harlev brings extensive experience in executive leadership, M&A, and business scaling from roles at Gizat Global Communications, LyteLoop Technologies, and other firms. The filing does not include any financial results or period-over-period comparisons, so no quantitative performance data is available.

• · Mr. Harlev holds a Bachelor of Laws degree from Radzyner Law School and an MBA from the Arison School of Business in Herzliya, Israel.
• · He previously served as COO of World-Link Communications, where he led a strategic acquisition that doubled the company's size.
• · As president of RRSat Global Communications Network, he grew the business into a major player in the US television market and significantly enhanced revenue over 18 months.
• · The filing includes extensive forward-looking statements and risk factors, including going concern doubts and customer concentration risks.

04-06-2026

Wesbanco, Inc. announced the retirement of Michael L. Perkins as Senior Executive Vice President and Chief Risk Officer, effective June 30, 2026, and entered into an Executive Transition and Consulting Agreement on June 3, 2026. Under the agreement, Mr. Perkins will serve as a consultant from July 1, 2026, through June 30, 2027, receiving a monthly consulting fee of $33,334, with continued equity vesting conditioned on compliance with a non-competition covenant. The filing does not include any financial results or period-over-period comparisons, so no positive or negative performance metrics are available.

• · Mr. Perkins' retirement was previously announced on January 22, 2026.
• · The consulting period expires on June 30, 2027, unless earlier terminated.
• · The agreement includes a non-competition covenant effective during the consulting term and for one year thereafter.
• · Continued vesting of equity awards is conditioned on compliance with the non-competition covenant.
• · The agreement also includes customary covenants: non-disparagement, cooperation, and return of company property.

04-06-2026

Knight-Swift Transportation Holdings Inc. announced the retirement of co-founder Kevin P. Knight as Executive Chairman, effective June 3, 2026. Lead Independent Director David Vander Ploeg has been appointed as Chairman. Mr. Knight will continue as a consultant for two years. The filing does not include any financial results or period-over-period comparisons.

• · Kevin Knight served as CEO from 1994 to 2014 and as Executive Chairman thereafter.
• · The 2017 merger of Knight Transportation and Swift Transportation is highlighted as the company's greatest collective achievement.
• · Adam Miller expressed gratitude for Knight's role in instilling a culture of safety, operational excellence, and financial discipline.

04-06-2026

On June 4, 2026, Yilin Lu resigned as President and Board member of LQR House Inc., effective immediately, with no disagreement with the company. The Board size was reduced from six to five directors.

• · Resignation was not due to any disagreement with the company's operations, policies, or practices.

04-06-2026

Innospec Inc. appointed Shelley Bausch as a Class II director effective July 1, 2026, and increased the board size from seven to eight. She will also serve on the Audit Committee. Her compensation includes an annual cash retainer of $100,000, an additional $5,000 for Audit Committee service, and an annual equity grant valued at $125,000.

• · Ms. Bausch's term runs until the 2027 annual meeting or until her successor is elected.
• · Equity grants are made under the Innospec Inc. Long-Term Incentive Omnibus Plan, typically in February, with restricted stock units vesting fully after three years.
• · No arrangement or understanding exists for her selection, and no related party transactions requiring disclosure under Item 404(a) were identified.

04-06-2026

Kaiser Aluminum Corporation held its 2026 Annual Meeting on June 4, 2026, where stockholders approved the amendment and restatement of the 2021 Equity and Incentive Compensation Plan, increasing available shares by 395,000 to a total of 1,183,000 shares. Three Class I directors were elected, and advisory votes on executive compensation (98.68% for) and ratification of Deloitte & Touche as auditor (98.20% for) passed with strong support. However, the approval of the Amended 2021 Plan received a lower 94.43% for vote, indicating some shareholder dissent.

• · The Amended 2021 Plan total shares available are 1,183,000, comprising 395,000 new shares, 263,000 from 2024, and 525,000 from 2021.
• · Director James D. Hoffman received 13,600,788 votes for and only 796 withheld, indicating near-unanimous support.
• · Glenda J. Minor received 14,118,306 votes for and 278,865 withheld, the highest for votes among nominees.
• · Brett E. Wilcox received 13,838,262 votes for and 558,909 withheld, the most withheld among nominees.
• · The advisory vote on executive compensation had 98.68% for, with 171,450 against and 18,088 abstentions.
• · Auditor ratification had 98.20% for, with 251,817 against and 20,125 abstentions.
• · The Amended 2021 Plan approval had 94.43% for, with 785,562 against and 16,307 abstentions, the lowest support among proposals.
• · All director nominees were elected with a majority of votes cast; broker non-votes were 722,574 for each director election.

04-06-2026

On June 1, 2026, Kathryn Gregory resigned from the Board of Directors of Longevity Health Holdings, Inc., effective immediately. The resignation was not due to any disagreement with the company regarding its operations, policies, or practices.

• · Resignation effective as of close of business on June 1, 2026.
• · No disagreement with the company's operations, policies, or practices was cited.

04-06-2026

Tempest Therapeutics appointed Drake Richey and John Yee, MD, MPH as independent directors effective June 4, 2026, bringing expertise in corporate finance and therapeutic product development. The company is advancing a pipeline of CAR-T cell therapy candidates for advanced cancers, but remains a clinical-stage biotech with no approved products and faces significant capital needs and operational risks as a going concern.

• · Mr. Richey serves as President of Bush & Company and previously held roles at Life Check, Wells Fargo, and Fitch Ratings.
• · Dr. Yee is SVP Medical Affairs at Apnimed and previously served as CMO at Sobi North America and in senior medical affairs roles at Vertex, AstraZeneca, and Genzyme.
• · Dr. Yee earned his MD from Harvard Medical School and MPH from Harvard T.H. Chan School of Public Health.
• · Tempest is headquartered in Brisbane, California and listed on Nasdaq under ticker TPST.
• · The company's forward-looking statements caution about risks including need for additional capital, unexpected safety/efficacy data, and potential going concern issues.

04-06-2026

Patterson-UTI Energy completed the redemption of all $482.5M of its 3.95% Senior Notes due 2028, funded by proceeds from a new $500M 6.050% Senior Notes due 2036 offering. Stockholders approved an amendment to the 2021 Long-Term Incentive Plan increasing shares by 28.9 million, and ratified PricewaterhouseCoopers as auditor. All ten director nominees were elected, though advisory say-on-pay received 311.5M votes for and 15.6M against, indicating some shareholder dissent.

• · The 2028 Notes were redeemed at 100% of principal plus accrued interest.
• · The new 6.050% Senior Notes due 2036 closed on May 19, 2026.
• · Advisory say-on-pay vote: 311,543,039 for, 15,554,952 against, 193,314 abstentions (broker non-votes 18,069,100).
• · Ratification of PricewaterhouseCoopers: 334,874,711 for, 10,307,536 against, 178,158 abstentions.
• · All ten director nominees received substantial support, with the lowest vote total being Julie J. Robertson at 317,669,255 votes for.
• · The amendment to the 2021 Plan was approved with 319,700,114 votes for, 7,391,767 against, 199,424 abstentions.

04-06-2026

Satellogic Inc. appointed retired U.S. Army Lieutenant General Michael E. Williamson as an independent Class III director, effective June 4, 2026. General Williamson brings over 30 years of defense acquisition and aerospace leadership, including senior roles at Lockheed Martin, to support Satellogic's scaling of its Earth observation constellation and expansion with government and commercial customers. The filing contains no financial data or period-over-period comparisons, so no quantitative metrics are available.

• · General Williamson served as Senior Vice President, Global Business Development and Strategy and President of Lockheed Martin International.
• · He holds a B.S. in Business Administration from Husson College, an M.S. in Material Acquisition Management from the Naval Postgraduate School, and a Ph.D. in Business Administration from Madison University.
• · He also holds executive and public policy credentials from Harvard University and Georgetown University.
• · Satellogic was founded in 2010 and trades on NASDAQ under the ticker SATL.

04-06-2026

Pacific Biosciences held its 2026 Annual Meeting on June 3, 2026, with approximately 65% of outstanding shares represented. Stockholders approved all four proposals, including the election of six Class III directors, ratification of Ernst & Young as independent auditor, an advisory vote on executive compensation, and an amendment to the 2020 Equity Incentive Plan to reserve an additional 16,000,000 shares. The board had previously approved the plan amendment on April 21, 2026, subject to stockholder approval.

• · The record date for the Annual Meeting was April 6, 2026.
• · Proposal 1 (Director Election): All six nominees received over 128 million votes 'For', with broker non-votes of 65,778,311 for each.
• · Proposal 2 (Auditor Ratification): Received 198,046,666 votes 'For', 3,990,483 'Against', and 972,226 'Abstain' — no broker non-votes.
• · Proposal 3 (Advisory Vote on Executive Compensation): 114,050,930 'For', 21,239,989 'Against', 1,940,145 'Abstain', with 65,778,311 broker non-votes.
• · Proposal 4 (Equity Plan Amendment): 114,865,820 'For', 20,469,132 'Against', 1,896,112 'Abstain', with 65,778,311 broker non-votes.
• · The amendment to the 2020 Plan was approved by the board on April 21, 2026, and subsequently by stockholders on June 3, 2026.

04-06-2026

Veea Inc. appointed Greg Deisher as COO and Executive Vice President, and Mark Tubinis as Executive Vice President, effective June 1, 2026. Deisher received options for 50,000 shares at $0.5518 per share, while Tubinis received a salary increase from $210,000 to $240,000 per year and options for 25,000 shares. No financial performance data was disclosed in this filing.

• · Greg Deisher has over 20 years of senior financial and operational leadership experience, including roles in Russia, China, and Southeast Asia.
• · Deisher served as CFO of Wallarm Inc (2024-2026) and Vapor IO, Inc. (2019-2024).
• · Deisher worked at PwC from 1990 to 1997 as a Senior Auditor in Dallas and Senior Manager, Tax & Legal in Almaty, Kazakhstan.
• · Deisher holds a bachelor's degree from Texas Tech University and completed graduate studies in Chinese language and China studies at University of Texas, Austin.
• · Deisher is a certified public accountant (CPA).
• · Mark Tubinis was previously Chief Commercial Officer and will continue in that role alongside his new EVP title.
• · Both option grants expire on June 1, 2031, and are subject to the terms of the 2024 Incentive Equity Plan.
• · No family relationships or material transactions requiring disclosure exist for either appointee.

04-06-2026

Upland Software, Inc. filed a Certificate of Amendment to effect a 1-for-10 reverse stock split of its common stock, effective June 17, 2026. The reverse split was approved by stockholders and the board, and no fractional shares will be issued; holders will receive cash in lieu of fractional shares based on the average closing price over the five trading days prior to filing. The par value remains $0.0001 per share.

• · The reverse stock split was approved by the board and stockholders in accordance with Delaware General Corporation Law Section 242.
• · The amendment was signed by CEO Sean Nathaniel on June 3, 2026.
• · Effective time: 12:01 a.m. New York City time on June 17, 2026.
• · No fractional shares will be issued; cash payments will be made for fractional interests.
• · The cash payment for fractional shares is based on the average closing price of the common stock on Nasdaq during the five consecutive trading days immediately preceding the filing date of the certificate.

04-06-2026

Alight, Inc. announced the appointment of Stephen A. Lasher as Chief Financial Officer, effective June 15, 2026. Lasher brings over 30 years of financial leadership experience from Digital Turbine, Vonage, and IBM, where he oversaw financial operations for an approximately $70 billion global sales organization. The filing does not disclose any financial results or period-over-period comparisons, so no negative or flat metrics are present.

• · Lasher most recently served as EVP and CFO of Nasdaq-listed Digital Turbine.
• · He previously served as CFO of Vonage, playing a critical role in executing strategic initiatives and driving revenue growth.
• · Lasher spent 24 years at IBM in senior financial management roles, including VP of Finance for IBM Global Markets and Integrated Accounts.
• · Alight serves over 30 million people through its benefits administration platform.

04-06-2026

Coronado Global Resources Inc. held its 2026 Annual General Meeting on June 3, 2026, where stockholders approved the issuance of up to 90,000,000 securities under the 2018 Equity Incentive Plan and elected six director nominees. All proposals received strong support, with the advisory vote on executive compensation passing with 77.9 million votes for and 8.0 million against, and stockholders selected a triennial frequency for future say-on-pay votes.

• · The advisory vote on executive compensation (Proposal 3) passed with 77,909,603 votes for, 7,984,679 against, and 66,963 abstentions.
• · Stockholders selected 'Every Three Years' as the frequency for future say-on-pay votes, with 77,435,988 votes for that option.
• · Ratification of Ernst & Young as independent auditor for FY2026 was approved with 85,820,835 votes for, 102,390 against.
• · Proposal 6 (issuance of up to 90,000,000 securities under the 2018 Equity Incentive Plan) passed with 85,539,438 votes for, 323,627 against.
• · Director Garold Spindler received the most votes for among common stockholders (85,804,180), while Greg Pritchard received the most votes withheld (3,539,991).
• · Laura Tyson was elected by the Series A Holder with 1 vote for and 0 withheld.

04-06-2026

Jack Henry & Associates announced the retirement of Board Chair David Foss, effective July 15, 2026, with Vice Chair and Lead Independent Director Matt Flanigan succeeding him. The transition is part of a planned succession, and no financial impact or performance metrics were disclosed in the filing.

• · David Foss joined Jack Henry in 1999, served as President from 2014 to 2022, CEO from 2016 to 2024, and Board Chair since 2021.
• · Matt Flanigan joined the Board in 2007, has served as Lead Director since 2012, and retired as EVP and CFO of Leggett & Platt in 2019.
• · No financial metrics, revenue figures, or performance data were included in the filing.

04-06-2026

Playboy, Inc. appointed Jennifer Cabalquinto as an independent director, filling a vacant seat and restoring the Board to seven directors with a majority of independent directors, thereby regaining compliance with Nasdaq independent director requirements. Cabalquinto brings extensive financial and governance experience from roles at 2K (CFO), Golden State Warriors (CFO), and various public and nonprofit boards. The filing contains no financial results or period-over-period comparisons, so no positive or negative metrics are available.

• · Cabalquinto currently chairs the board of KQED and previously chaired its Finance Committee.
• · She serves on the board of American Century Investments California funds, chairing the Audit Committee and sitting on the Technology & Risk Committee and Portfolio Committee.
• · She was an independent director and Audit Committee Chair of Sabio Holdings Inc. (2022-2024).
• · She served as CFO of 2K (Take-Two) from 2021 to 2023 and CFO of Golden State Warriors Sports from 2013 to 2020.

04-06-2026

World Acceptance Corp announced the termination of Janet L. Matricciani as Interim President and CEO effective June 3, 2026, with no disagreement cited. J. Tobin Turner, age 51, was designated as Principal Executive Officer for SEC reporting purposes while continuing as EVP and COO. Ms. Matricciani will receive severance including a $350,000 cash inducement award retention, bi-weekly base salary of $38,461.54 through April 12, 2027, and retention of 592 vested restricted shares.

• · Mr. Turner, age 51, has served as EVP and COO since February 2026, previously as SVP of Marketing and Analytics from 2023 to 2026.
• · Mr. Turner was an Associate Professor of Economics and Business Administration at Presbyterian College from 2010-2023, including serving as Department Chair.
• · No changes to Mr. Turner's compensation were made in connection with his designation as Principal Executive Officer.
• · There are no family relationships or material interests requiring disclosure under Item 404(a).
• · The Board is continuing its search for a permanent CEO successor.

04-06-2026

Viemed Healthcare held its Annual General and Special Meeting on June 4, 2026, where shareholders approved a second amendment to the 2024 Long Term Incentive Plan, increasing the maximum common shares reserved for issuance to 7,696,717 (including up to 1,000,000 incentive stock options). All seven director nominees were elected, with Sabrina Heltz receiving notably lower support (79.76% for) compared to other directors (93.28%–97.67% for). Shareholders also ratified the appointment of Ernst & Young as auditors (97.59% for) and approved the say-on-pay advisory vote (93.21% for).

• · The Second Amendment to the 2024 LTIP was approved by the Board on April 7, 2026, and ratified by shareholders at the June 4, 2026 meeting.
• · Sabrina Heltz received only 79.76% of votes for, with 20.24% withheld, significantly lower than the other six directors who all received over 93% support.
• · Broker non-votes for director election totaled 5,139,303 shares.
• · The say-on-pay vote passed with 93.21% for, 6.20% against, and 0.59% abstaining.
• · The auditor appointment passed with 97.59% for, 2.41% withheld, and no broker non-votes.

04-06-2026

RemSleep Holdings Inc. (RMSL) filed an 8-K reporting a change of control and complete overhaul of its board and officers following stock purchase agreements dated May 20, 2026. Roman Israel Wood and Anita L. Michaels transferred significant blocks of Preferred and Common stock to 1000152403 ONTARIO INC and Miro Zecevic, triggering the resignation of all prior senior officers and directors. The incoming leadership team consists of Teresita Rubio (Treasurer & Chairman), Sanja Pekovic (President & CEO), and Irina Veselinovic (Secretary).

• · The stock purchase agreement involved Roman Israel Wood selling cumulative ~49.6M shares (all classes) and Anita L. Michaels selling ~11.5M shares (all classes) to the respective buyers.
• · The new control party is 1000152403 ONTARIO INC, a Canadian corporation, for Preferred stock classes; common stock was purchased by Miro Zecevic individually.
• · Michaels' shares were sold subject to Rule 144; Wood's sale was characterized as 'control' stock for Preferred A, B, C.
• · The company will submit a new application to OTC Markets to reflect the change of control.
• · The filing does not disclose any consideration or purchase price for the stock sales, and no forward-looking financial guidance or operational plan was provided.

04-06-2026

At GM's 2026 Annual Meeting held on June 2, 2026, shareholders elected all 10 director nominees and approved all board proposals, including an amendment to the 2020 Long-Term Incentive Plan that increases available shares by 27 million and extends the plan to 2036. However, shareholder proposals to separate the Chair and CEO roles and to report on human rights standards for indigenous peoples were both rejected by wide margins.

• · Shareholders ratified Ernst & Young LLP as independent auditor for 2026 with 762,459,672 votes for and only 2,639,409 against.
• · Advisory vote on named executive officer compensation passed with 642,847,031 votes for (93.5% of votes cast, excluding broker non-votes).
• · The frequency of future advisory votes on executive compensation was set to 1 year (672,645,795 votes for 1 year vs. 14,886,074 for 3 years).
• · The LTIP amendment was approved with 488,215,468 votes for (71.0% of votes cast) and 199,829,891 against.
• · The shareholder proposal to separate Chair and CEO roles was defeated: 152,263,297 for vs. 531,635,494 against.
• · The shareholder proposal on human rights standards for indigenous peoples was defeated: 101,084,999 for vs. 582,293,907 against.
• · Director Patricia F. Russo received the lowest support among nominees with 608,267,120 votes for and 80,186,615 against (88.4% of votes cast).

04-06-2026

Lipocine Inc. held its annual general meeting on June 3, 2026, where shareholders approved the Sixth Amended and Restated 2014 Stock and Incentive Plan, increasing individual award limits from 25,000 to 100,000 shares and authorizing an additional 400,000 shares (total now 1,000,000). All four director nominees were elected, and the appointment of Tanner LLC as independent auditor for FY2026 was ratified. The advisory vote on executive compensation passed with 1,626,360 votes for and 208,110 against, indicating majority support but notable dissent.

• · Shareholder approval of the 2014 Plan amendment was relatively close: 1,520,190 For vs 313,830 Against, with 27,220 Abstentions.
• · Advisory vote on executive compensation had 208,110 votes Against (11.3% of votes cast), indicating some shareholder concern.
• · Broker non-votes were 2,916,331 on director elections, executive compensation, and the stock plan amendment, reflecting significant unvoted shares.
• · Ratification of Tanner LLC as auditor passed overwhelmingly with 4,538,146 For and only 178,276 Against.
• · Adjournment proposal passed with 4,117,918 For vs 606,404 Against.

04-06-2026

Myriad Genetics held its 2026 Annual Meeting on June 4, 2026, where shareholders elected three Class III directors (Paul M. Bisaro, Rashmi Kumar, and Lee N. Newcomer), ratified Ernst & Young as independent auditor, approved executive compensation on an advisory basis, and approved amendments to the 2012 Employee Stock Purchase Plan (adding 4,000,000 shares) and the 2026 Employee, Director and Consultant Equity Incentive Plan (authorizing up to 8,659,575 shares). All proposals passed with significant shareholder support.

• · Quorum of 77,758,631 shares (82.33%) was present.
• · Proposal 1 director elections: Paul M. Bisaro received 61,842,900 votes for, 637,156 against, 23,264 abstentions; Rashmi Kumar received 60,399,633 for, 2,071,375 against, 32,312 abstentions; Lee N. Newcomer received 61,576,936 for, 894,837 against, 31,547 abstentions.
• · Proposal 2 (auditor ratification): 76,302,595 for, 1,391,172 against, 64,864 abstained.
• · Proposal 3 (advisory say-on-pay): 59,356,710 for, 3,098,966 against, 47,644 abstained, with 15,255,311 broker non-votes.
• · Proposal 4 (Purchase Plan amendment): 61,812,338 for, 650,741 against, 40,241 abstained.
• · Proposal 5 (2026 Plan): 59,389,193 for, 3,066,087 against, 48,040 abstained.
• · Broker non-votes were 15,255,311 for Proposals 1, 3, 4, and 5.

04-06-2026

WD-40 Company announced four executive leadership appointments as part of a planned transition to strengthen organizational alignment and support long-term strategic priorities. Patricia Olsem will become chief strategy and innovation officer, Claudia Fenske chief brand and marketing officer, Sara Hyzer president of the Americas division (while continuing as CFO until a successor is appointed), and Nicholas Giordano vice president, corporate controller, and chief accounting officer. The company reported net sales of $620.0 million in fiscal year 2025, but the filing does not provide period-over-period comparisons or any negative performance metrics.

• · Patricia Olsem has been with the company since 2005 and currently serves as president, Americas division.
• · Claudia Fenske has been with the company since 2012 and currently serves as vice president, global brand and innovation.
• · Sara Hyzer has been with the company since 2021 and previously spent over 20 years at PricewaterhouseCoopers LLP, including six years as an audit partner.
• · Nicholas Giordano has been with the company since 2014 and currently serves as vice president, corporate controller.
• · Olsem and Fenske will remain in their current roles through the end of fiscal year 2026, transitioning in Q1 FY2027.
• · Hyzer will continue as CFO during the transition until a new CFO is appointed.
• · Giordano's appointment as vice president, corporate controller, and chief accounting officer is effective June 29, 2026.
• · The company's products are available in more than 176 countries and territories worldwide.

04-06-2026

Sturm, Ruger & Company, Inc. (RGR) announced on June 1, 2026, that its Board of Directors, upon recommendation from the Compensation Committee, adjusted the compensation package for President and CEO Todd W. Seyfert. The new package includes an $800,000 base salary, a target cash bonus of 100% of base salary, annual performance-based equity awards of 150% of base salary, and annual time-based equity awards of 150% of base salary. The Board also granted supplemental restricted stock unit awards to align with prior awards from March 6, 2026.

• · Supplemental restricted stock unit awards granted to Mr. Seyfert have vesting conditions and dates mirroring those from awards granted on March 6, 2026.
• · No other executive officers' compensation was adjusted in this filing.

04-06-2026

VAALCO Energy held its Annual Meeting on June 4, 2026, where stockholders approved an amendment to the 2020 Long Term Incentive Plan, increasing authorized shares by 5.25M to 20M and extending the plan term to 2036. All five director nominees were elected, and KPMG LLP was ratified as auditor. Advisory say-on-pay and the LTIP amendment passed with majority support, though the LTIP amendment received 7.36M against votes.

• · The LTIP amendment increased authorized shares by 5,250,000 to a total of 20,000,000 shares.
• · The LTIP term was extended by ten years through June 4, 2036.
• · All five director nominees were elected with votes for ranging from 50.8M to 54.7M.
• · Ratification of KPMG passed with 73.7M for, 0.18M against, and 0.75M abstentions.
• · Advisory say-on-pay received 53.9M for, 1.5M against, and 0.69M abstentions.
• · The LTIP amendment received 47.9M for, 7.4M against, and 0.75M abstentions.
• · Broker non-votes were 18.6M on all non-routine matters (director elections, say-on-pay, LTIP amendment).

04-06-2026

Medpace Holdings, Inc. appointed Brad W. Hansman as Executive Vice President, Operations, effective June 1, 2026. Mr. Hansman, a 15-year company veteran, will share principal operating officer duties with Susan E. Burwig. His compensation includes an annual base salary of $492,250 and eligibility for short-term and long-term incentive plans.

• · Mr. Hansman joined Medpace in April 2011 in Finance & Accounting and held various roles until July 2015.
• · Since August 2015, he has held operations leadership roles including Executive Director, Vice President, and Senior Vice President overseeing study start-up, logistics, regulatory affairs, and medical writing.
• · He holds a Bachelor of Business Administration in Accounting from Eastern Kentucky University and is a Certified Public Accountant (inactive).
• · Mr. Hansman has no family relationships with any current director, director nominee, or executive officer, and no reportable transactions under Item 404(a).
• · He will enter into the company's standard indemnification agreement for directors and executive officers.

04-06-2026

Monster Beverage Corporation announced that director Mark J. Hall will resign from the Board effective August 1, 2026, and as an employee of subsidiary Monster Energy US LLC effective April 1, 2027. The Board will reduce its size from ten to nine directors. Mr. Hall confirmed his resignation is not due to any disagreement with the company.

• · Mark J. Hall's resignation as director is effective August 1, 2026.
• · His resignation as employee of Monster Energy US LLC is effective April 1, 2027.
• · The Board size is being reduced from ten to nine directors.
• · Mr. Hall stated his resignation is not due to any disagreement with the company, its management, the Board, or any committee.

04-06-2026

On June 2, 2026, Plug Power Inc. announced that Class I director Kavita Mahtani will resign from the Board effective June 11, 2026, to focus on her new executive role at Wells Fargo. Ms. Mahtani, who served on the Board since April 2022 and was a member of the Audit Committee and Strategy & Financing Committee, confirmed her departure is not due to any disagreement with the Company. The Company expressed gratitude for her contributions.

• · Ms. Mahtani served on the Board since April 2022.
• · She was a member of the Audit Committee and Strategy & Financing Committee.
• · Her resignation is effective June 11, 2026.
• · The resignation is not due to any disagreement with the Company's operations, policies, or practices.